Filing Details
- Accession Number:
- 0001562180-24-000808
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-30 16:53:11
- Reporting Period:
- 2024-01-26
- Accepted Time:
- 2024-01-30 16:53:11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1314102 | Eyepoint Pharmaceuticals Inc. | EYPT | Laboratory Analytical Instruments (3826) | 262774444 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1574261 | A. Dario Paggiarino | C/O Eyepoint Pharmaceuticals, Inc. 480 Pleasant Street Watertown MA 02472 | Chief Medical Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-01-26 | 15,609 | $12.90 | 52,114 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-01-26 | 51 | $13.13 | 52,165 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-01-26 | 33,665 | $13.13 | 85,830 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-01-26 | 51 | $25.41 | 85,779 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-01-26 | 15,609 | $25.41 | 70,170 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-01-26 | 33,665 | $25.77 | 36,505 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-01-26 | 51 | $0.00 | 51 | $13.13 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-01-26 | 33,665 | $0.00 | 33,665 | $13.13 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-01-26 | 15,609 | $0.00 | 15,609 | $12.90 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 51,253 | 2031-02-09 | No | 4 | M | Direct | |
| 17,588 | 2031-02-09 | No | 4 | M | Direct | |
| 1,026 | 2030-02-28 | No | 4 | M | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $25.88. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.00 to $26.62. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2022 and the remainder ratably, on a monthly basis, over the remaining three years.
- The option to purchase vests and becomes exercisable ratably in forty-eight monthly installments which began March 28, 2020
Billionaire Hedge Funds
